{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:01:40Z","timestamp":1787256100913,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,17]]},"DOI":"10.7759\/cureus.50692","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:16Z","timestamp":1702857616000},"source":"Crossref","is-referenced-by-count":10,"title":["Exacerbation of Thymoma-Associated Myasthenia Gravis Following Efgartigimod Treatment Related to Anti-acetylcholine Receptor Antibody Overshoot: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Kentaro","family":"Kawama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Warabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Bokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJ. Myasthenia gravis. Nat Rev Dis Primers. 2019, 5:30. 10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar MK","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022, 11: 1597. 10.3390\/jcm11061597","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al.. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021, 20:526-36. 10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo YA","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022, 82:341-8. 10.1007\/s40265-022-01678-3","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27341","article-title":"Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis","volume":"64","author":"Ching J","year":"2021","unstructured":"Ching J, Richards D, Lewis RA, Li Y. Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis. Muscle Nerve. 2021, 64:483-7. 10.1002\/mus.27341","journal-title":"Muscle Nerve"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12923","article-title":"Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients","volume":"55","author":"Yamada C","year":"2015","unstructured":"Yamada C, Ramon DS, Cascalho M, Sung RS, Leichtman AB, Samaniego M, Davenport RD. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients. Transfusion. 2015, 55:727-35. 10.1111\/trf.12923","journal-title":"Transfusion"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920100410","article-title":"Immunologic rebound","volume":"10","author":"Dau PC","year":"1995","unstructured":"Dau PC. Immunologic rebound. J Clin Apher. 1995, 10:210-7. 10.1002\/jca.2920100410","journal-title":"J Clin Apher"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22036","article-title":"Failure of double filtration plasmapheresis to treat severe pemphigus vulgaris: a case report","volume":"38","author":"Liu Y","year":"2023","unstructured":"Liu Y, Wang F. Failure of double filtration plasmapheresis to treat severe pemphigus vulgaris: a case report. J Clin Apher. 2023, 38:491-4. 10.1002\/jca.22036","journal-title":"J Clin Apher"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27974","article-title":"Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"68","author":"Katyal N","year":"2023","unstructured":"Katyal N, Halldorsdottir K, Govindarajan R, et al.. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve. 2023, 68:762-6. 10.1002\/mus.27974","journal-title":"Muscle Nerve"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31951-8","article-title":"Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma","volume":"13","author":"Yasumizu Y","year":"2022","unstructured":"Yasumizu Y, Ohkura N, Murata H, et al.. Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma. Nat Commun. 2022, 13:4230. 10.1038\/s41467-022-31951-8","journal-title":"Nat Commun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon AE","year":"2015","unstructured":"Nixon AE, Chen J, Sexton DJ, et al.. Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates. Front Immunol. 2015, 6:176. 10.3389\/fimmu.2015.00176","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon S","year":"2018","unstructured":"Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018, 78:367-76. 10.1007\/s40265-018-0875-9","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard JF Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, et al.. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017, 16:976-86. 10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51285.x","article-title":"Humoral pathogenesis of myasthenia gravis","volume":"505","author":"Drachman DB","year":"1987","unstructured":"Drachman DB, de Silva S, Ramsay D, Pestronk A. Humoral pathogenesis of myasthenia gravis. Ann N Y Acad Sci. 1987, 505:90-105. 10.1111\/j.1749-6632.1987.tb51285.x","journal-title":"Ann N Y Acad Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/208050-exacerbation-of-thymoma-associated-myasthenia-gravis-following-efgartigimod-treatment-related-to-anti-acetylcholine-receptor-antibody-overshoot-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:48Z","timestamp":1707509388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/208050-exacerbation-of-thymoma-associated-myasthenia-gravis-following-efgartigimod-treatment-related-to-anti-acetylcholine-receptor-antibody-overshoot-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,17]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.50692","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,17]]}}}